Tom Dayspring

Tom Dayspring, a leading expert in clinical lipidology, dives deep into the intricacies of atherosclerotic cardiovascular disease (ASCVD), a major global health concern. He explains how ASCVD develops silently over decades, emphasizing the importance of early detection. Dayspring discusses the critical role of apolipoprotein B (apoB) and the often-overlooked risk factors, including insulin resistance and kidney health. Additionally, he explores how cholesterol impacts brain health, debunking myths about statins, and highlights the significance of dietary choices in managing cardiovascular risk.

Allan Sniderman, a leading expert in lipoprotein metabolism, and Tom Dayspring, a specialist in atherosclerotic cardiovascular disease (ASCVD), share their insights on cardiovascular health. They discuss the limitations of standard lipid metrics and highlight apoB as a superior risk assessment tool. The conversation dives into the importance of early intervention and challenges misconceptions around cholesterol, advocating for proactive measures against ASCVD. Discover how understanding these factors can significantly alter prevention strategies.

Tom Dayspring, a board-certified lipidologist and educator, explains how the brain handles cholesterol independently from the body. He explores APOE isoforms and why APOE4 raises Alzheimer’s risk. He discusses cholesterol transport in the brain, links to amyloid and tau, and how statins, ezetimibe, omega-3s, and CETP inhibitors may affect brain health.

Dr. Tom Dayspring, a renowned lipidologist with 37 years of experience, returns to share fresh insights into cardiovascular disease and lipidology. He emphasizes the significance of atherogenic lipoproteins in atherosclerosis, particularly the importance of apolipoprotein B (apoB) over traditional metrics. Dayspring delves into revolutionary lipid-lowering therapies, including new findings on EPA and DHA, and discusses lipoprotein(a) (Lp(a)) as a critical but often overlooked risk factor. This engaging dialogue sheds light on the evolving landscape of cardiovascular health.

HDL’s role in moving cholesterol around turns out to be far more complicated than its familiar “good cholesterol” label suggests. The conversation explores apolipoproteins, remnant particles, and the tangled traffic between lipoproteins, then revisits the rise and fall of several CETP inhibitor drugs. It also examines why cholesterol measures can tell very different stories from particle counts.